Skip to main content
. 2016 Jan 8;7(2):213–226. doi: 10.1002/wrna.1326

Table 2.

Vaccine Development Dependent on NCs

Virus Design Responses References
Influenza virus Immunodominant epitopes Immunodominant CD4(+)/CD8(+) T‐cell responses 97, 98
Recombinant PIV5 encoding NC Humoral and T‐cell responses 96
HIV Zinc inhibitors Strong antiviral ability but quite toxic 99
Noncovalent NC inhibitors Great specificity and less toxic 99, 100, 101, 102, 103, 104, 105
SARS‐CoV DNA vaccine expressing NC fusing with calreticulin B‐cell and T‐cell and specific humoral response 106
DNA vaccine of NC fused with lysosome‐associated membrane protein Long‐lasting T‐cell memory response 107
DNA vaccine plasmids expressing NC and IL‐12 IL‐12 plays an immunoadjuvant and better specific humoral and cellular immunity 108
Immunodominant epitopes B‐cell and T‐cell responses 109, 110
Expressing from Lactobacillus lactis Significant NC‐specific IgG in the sera 111
Expressing in tobacco Strong humoral and cellular responses 112

HIV, human immunodeficiency virus; IL‐12, interleukin‐12; NCs, nucleocapsid proteins; PIV5, parainfluenza virus 5; SARS, severe acute respiratory syndrome coronavirus.